Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment

Cytokine

Volumn 73, Issue 2, 2015, Pages 245-252

  Cho, Hyo Jung ^a   Kim, Soon Sun ^a   Ahn, Seun Joo ^a   Park, Sun Young ^a   Park, Joo Han ^a   Kim, Jae Keun ^a   Wang, Hee Jung ^a   Cheong, Jae Youn ^a   Cho, Sung Won ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Cytokine; Hepatitis B, chronic; Hepatocellular carcinoma; Prognosis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT DURATION; BLOOD; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; TUMOR RECURRENCE; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS;

EID: 84925201192     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.027     Document Type: Article

References (46)

1. Lu T., Seto W.K., Zhu R.X., Lai C.L., Yuen M.F. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013, 19:8887-8894.
2. Bruix J., Sherman M. American association for the study of liver, diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
3. Hatzaras I., Bischof D.A., Fahy B., Cosgrove D., Pawlik T.M. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014, 21:758-766.
4. Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011, 98:1210-1224.
5. Portolani N., Coniglio A., Ghidoni S., Giovanelli M., Benetti A., Tiberio G.A., et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006, 243:229-235.
6. Ercolani G., Grazi G.L., Ravaioli M., Del Gaudio M., Gardini A., Cescon M., et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003, 237:536-543.
7. Jang J.W., Oh B.S., Kwon J.H., You C.R., Chung K.W., Kay C.S., et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 2012, 60:686-693.
8. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
9. Chan S.L., Mo F.K., Wong C.S., Chan C.M., Leung L.K., Hui E.P., et al. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012, 118:3984-3992.
10. Tangkijvanich P., Thong-Ngam D., Mahachai V., Theamboonlers A., Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007, 13:4345-4349.
11. Zheng Y.B., Zhao W., Liu B., Lu L.G., He X., Huang J.W., et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev 2013, 14:5527-5531.
12. Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., Fan S.T. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007, 14:1835-1845.
13. Pang R.W., Poon R.T. Diagnosis: novel prognostic biomarkers in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2012, 9:691-692.
14. Singhal A., Jayaraman M., Dhanasekaran D.N., Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol 2012, 82:116-140.
15. Ferguson-Smith A.C., Chen Y.F., Newman M.S., May L.T., Sehgal P.B., Ruddle F.H. Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics 1988, 2:203-208.
16. Heikkila K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008, 44:937-945.
17. Kinoshita A., Nishino H. IL-6, a promising tumor marker and prognostic indicator in patients with HCC?. J Tumor 2014, 2:142-144.
18. Masuzaki R., Karp S.J., Omata M. New serum markers of hepatocellular carcinoma. Semin oncol 2012, Elsevier, p. 434-9.
19. Giannitrapani L., Soresi M., Giacalone A., Campagna M.E., Marasa M., Cervello M., et al. IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 2011, 15:183-186.
20. Ueda T., Shimada E., Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994, 29:423-429.
21. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
22. Porta C., De Amici M., Quaglini S., Paglino C., Tagliani F., Boncimino A., et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008, 19:353-358.
23. Tan C.H., Low S.C., Thng C.H. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol 2011, 2011:519783.
24. Kee K.M., Wang J.H., Lee C.M., Chen C.L., Changchien C.S., Hu T.H., et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer 2007, 120:2650-2655.
25. Alison M.R., Nicholson L.J., Lin W.-R. Chronic inflammation and hepatocellular carcinoma. Inflammation and gastrointestinal cancers 2011, Springer, p. 135-48.
26. Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin cancer biol 2011, Elsevier, p. 35-43.
27. Othman M.S., Aref A.M., Mohamed A.A., Ibrahim W.A. Serum levels of interleukin-6 and interleukin-10 as biomarkers for hepatocellular carcinoma in Egyptian patients. ISRN Hepatol 2013, 2013:1-9.
28. Pang X.H., Zhang J.P., Zhang Y.J., Yan J., Pei X.Q., Zhang Y.Q., et al. Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma. Hepatogastroenterology 2011, 58:1687-1693.
29. Moran D.M., Mattocks M.A., Cahill P.A., Koniaris L.G., McKillop I.H. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008, 147:23-33.
30. Moran D.M., Mayes N., Koniaris L.G., Cahill P.A., McKillop I.H. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int 2005, 25:445-457.
31. Klausen P., Pedersen L., Jurlander J., Baumann H. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene 2000, 19:3675-3683.
32. Kim H., Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 1999, 19:5326-5338.
33. Hammad L.N., Abdelraouf S.M., Hassanein F.S., Mohamed W.A., Schaalan M.F. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?. J Immunotoxicol 2013, 10:380-386.
34. He G., Dhar D., Nakagawa H., Font-Burgada J., Ogata H., Jiang Y., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013, 155:384-396.
35. Shiina S., Tateishi R., Arano T., Uchino K., Enooku K., Nakagawa H., et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012, 107:569-577. quiz 78.
36. Poon R.T., Fan S.T., Lo C.M., Liu C.L., Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002, 235:373-382.
37. Hanazaki K., Kajikawa S., Shimozawa N., Mihara M., Shimada K., Hiraguri M., et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000, 191:381-388.
38. Dehqanzada Z.A., Storrer C.E., Hueman M.T., Foley R.J., Harris K.A., Jama Y.H., et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006, 12:478-486.
39. Howell W.M., Rose-Zerilli M.J. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006, 5:143-149.
40. Ganapathi S.K., Beggs A.D., Hodgson S.V., Kumar D. Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance. Br J Cancer 2014, 111:1581-1589.
41. Kaskas N.M., Moore-Medlin T., McClure G.B., Ekshyyan O., Vanchiere J.A., Nathan C.A. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngol Head Neck Surg 2014, 140:5-11.
42. Kamiyama T., Nakanishi K., Yokoo H., Kamachi H., Tahara M., Kakisaka T., et al. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol 2012, 10:107.
43. Wu C.Y., Chen Y.J., Ho H.J., Hsu Y.C., Kuo K.N., Wu M.S., et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012, 308:1906-1914.
44. Kao W.Y., Chiou Y.Y., Hung H.H., Chou Y.H., Su C.W., Wu J.C., et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol 2011, 23:528-536.
45. Chau G.Y., Wu C.W., Lui W.Y., Chang T.J., Kao H.L., Wu L.H., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000, 231:552-558.
46. Zhang Y., Zhang B., Zhang A., Li X., Liu J., Zhao J., et al. IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells. Braz J Med Biol Res 2013, 46:32-38.